 Scott Armstrong, MD, PhD
Previous |
Next
 |
Return to Search Results
Departments/Divisions
Hematology/Oncology
Medicine
Specialty
oncology
Service/Program
Oncology
Clinical Title
Attending Staff in Medicine
Academic Appointment
Assistant Professor of Pediatrics, Harvard Medical School
|
| |
|
Medical/Dental School
University of Texas Southwestern, Dallas, TX (1996)
Fellowship
Children's Hospital Boston / Dana Farber Cancer Institute, Boston, MA (1998-2001)
MLL-dependent Myeloid Leukemia, Cancer Stem Cells
- Use of expression profiling to identify Flt3 and other genes that characterize MLL-rearranged leukemias. (Nat Genet 30:41, 2002)
- Application of FLT3 tyrosine kinase inhibitors to the treatment of MLL-rearranged leukemias (Cancer Cell 3:173, 2003; Blood 106:2454, 2005)
- Hox gene dysregulation in MLL-rearranged T-lineage and B-precursor acute leukemias (Blood 102:262, 2003)
- Definition of antiapoptotic factors required for cancer cell survival (Cancer Cell 9:351, 2006)
- Molecular biogenesis of leukemic stem cells (Nature 442:818, 2006)
- Research site for Scott Armstrong, MD, PhD
|
Previous |
Next
|
Return to Search Results
|
|
|
